ClinicalTrials.gg
Status unknownNCT03633760Updated Jan 10, 2019

Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese Population

A Phase 1 interventional study of Bilastine 40mg single dose and Bilastine 20mg single-dose followed by multiple-dose in Pharmacokinetics, sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-10.

Sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd (part of Menarini Group) · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-dose and multiple-dose, open-label, single-centre pharmacokinetic (PK) study which will be conducted in Phase I Clinical Trial Centre, Chinese University of Hong Kong, to evaluate pharmacokinetics (PK) of different levels of single-dose and multiple-dose of bilastine in healthy Chinese subjects.

Read the detailed description

This is a single-dose and multiple-dose, open-label, single-centre pharmacokinetic (PK) study, to evaluate pharmacokinetics (PK) of different levels of single-dose and multiple-dose of bilastine in healthy Chinese subjects. Total 24 subjects will be enrolled into the study and divided into 2 cohorts, 12 subjects in each cohort.

Single-dose only cohort treatment duration is 1 day and receive a single dose of 40 mg of bilastine then collect PK blood sample. Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9 and collect PK blood samples. The primary objective of the study is to determine the PK properties of orally administered bilastine in healthy Chinese population. The secondary objective of the study is to evaluate the safety and tolerability of bilastine administered as a single and multiple doses in healthy Chinese subjects.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

A.Menarini Asia-Pacific Holdings Pte Ltd is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted after A.Menarini Asia-Pacific Holdings Pte Ltd became part of Menarini Group.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ethnic Chinese males and females between 18 and 45 years of age (inclusive).
  2. Having voluntarily given their to participate in the study after receiving information about the design, aims and potential risks that could result from the study and being informed that they could refuse to take part in or withdraw from the study at any time.
  3. Body mass of no less than 50 kg. : 19 to 24 kg/m2 (inclusive).
  4. No abnormal findings from the physical examination, vital signs check, (ECG), medical history, or clinical laboratory results during screening and pre-dosing of Day 1.
  5. A negative screen for and .
  6. A negative urine or breathalyzer screen for alcohol and negative urine screen for drugs of abuse.
  7. Are non-tobacco / nicotine users (within 3 months prior to screening visit).
  8. A negative serum pregnancy test for female subjects.
  9. Subjects who are willing to comply with the restrictions for this study:

    1. True abstinence.
    2. Barrier methods with spermicidal use. The use of barrier contraceptives should always be supplemented with the use of a spermicide, where available.
    3. Intrauterine devices: intrauterine device with the use of condom or spermicide.
    4. Sterilization of male subjects (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).

Exclusion criteria

Exclusion Criteria:

  1. History of gastrointestinal, renal, hepatic, neurologic, haematological, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, jeopardises the safety of the subject or will impact the validity of the study results.
  2. History of allergic or adverse response to antihistamine drugs.
  3. Participated in a clinical trial within 90 days prior to screening.
  4. Donated blood within 90 days prior to screening.
  5. Donated plasma within 90 days prior to screening.
  6. Abnormal diet or substantial changes in eating habits within 30 days prior to screening.
  7. Used any prescription medication within 14 days prior to or during screening, especially any known P-glycoprotein transporter inhibitors agents (ketoconazole, erythromycin, ciclosporin, digoxin, etc.).
  8. Used any prescription or any over-the-counter medication, herbal or traditional Chinese medication within 7 days prior to or during screening.
  9. Intake of grapefruit or any other citrus fruit, fruit juice or cranberries within 72 hours prior to study drug administration.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Bilastine 40mg single dose

    12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine

    Drug: Bilastine 40mg single dose

  • Experimental
    Bilastine 20mg multiple dose

    12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9

    Drug: Bilastine 20mg single-dose followed by multiple-dose

Interventions

  • Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine

  • DrugBilastine 20mg single-dose followed by multiple-dose

    Drug page: Bilastine

    Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (Cmax)

    observed maximum plasma concentration

    Time frame: day1, day4 to day9

  2. Pharmacokinetic (tmax)

    time to reach Cmax

    Time frame: day1, day4 to day9

  3. Pharmacokinetic (λz)

    terminal rate constant

    Time frame: day1, day4 to day9

  4. Pharmacokinetic (t½)

    terminal half-life

    Time frame: day1, day4 to day9

  5. Pharmacokinetic [AUC(0-24)]

    area under the plasma concentration-time curve from zero to 24 hours after study drug administration

    Time frame: day1

  6. Pharmacokinetic [AUC(0-last)]

    from time zero to the time of last quantifiable concentration

    Time frame: day1

  7. Pharmacokinetic [AUC(0-inf)]

    from time zero extrapolated to infinity

    Time frame: day1

  8. Pharmacokinetic (CL/F)

    apparent systemic clearance following oral dosing

    Time frame: day1, day4 to day9

  9. Pharmacokinetic (Vz/F)

    apparent volume of distribution during terminal phase following oral dosing

    Time frame: day1, day4 to day9

  10. Pharmacokinetic [AUC(0-inf)/D]

    dose-normalized AUC(0-inf)

    Time frame: day1

  11. Pharmacokinetic (Cmax/D)

    dose-normalized Cmax

    Time frame: day1

  12. Pharmacokinetic (Cavg)

    average concentration over the study drug interval

    Time frame: day4 to day9

  13. Pharmacokinetic [AUC(0-tau)]

    area under the plasma concentration-time curve during the dosing interval following multiple dosing

    Time frame: day4 to day9

  14. Pharmacokinetic (FI)

    fluctuation index

    Time frame: day4 to day9

  15. Pharmacokinetic (LI)

    linearity index

    Time frame: day4 to day9

  16. Pharmacokinetic [RAUC(0-tau)]

    accumulation ratio for AUC(0-tau)

    Time frame: day4 to day9

  17. Pharmacokinetic (RCmax)

    accumulation for Cmax

    Time frame: day4 to day9

Secondary outcomes

  1. Adverse events

    Safety will be evaluated with summary of Adverse Events

    Time frame: day1 to day16

07

Study locations

1 of 1 sites recruiting
  • Phase I Clinical Trial Centre, Chinese University of Hong Kong
    Hong Kong, Hong Kong 999077, China
    Recruiting
    • Andrea Luk, Professor · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2018 (actual). Primary completion is estimated for Apr 2019, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2018
First posted
Aug 16, 2018
StartActual
Aug 28, 2018
Primary completionEst.
Apr 30, 2019
CompletionEst.
Jul 31, 2019
Last update
Jan 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03633760
Responsible party
Sponsor
First posted
Aug 16, 2018
Start date
Aug 28, 2018
Primary completion
Apr 30, 2019 (estimated)
Completion
Jul 31, 2019 (estimated)
Last update
Jan 10, 2019

Study contacts

Maria Carolina De Quiroz, MD
Contact
carolina.dequiroz@menariniapac.com
+65 6494 7226
Andrea Luk, Professor
principal investigator · Phase I Clinical Trial Centre, Chinese University of Hong Kong

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion